New drug combo aims to improve stomach cancer surgery outcomes
Disease control
Not yet recruiting
This study tests whether adding the drug adebrelimab to standard chemotherapy (S-1 and oxaliplatin) before and after surgery helps people with stomach or gastroesophageal junction cancer live longer without the cancer returning. About 874 adults aged 18-74 with locally advanced, …
Phase: PHASE3 • Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 11, 2026 20:50 UTC